Zymeworks Inc.
Zymeworks develops commercial and clinical-stage biotherapeutics including the bispecific antibody zanidatamab and multispecific antibodies using its Azymetric platform.
SCHEDULE 13G/ANov 16Latest SEC filing
Nov 9Latest story
November 2026
October 2026
September 2026
August 2026
June 2026